Pyxis Oncology, Inc.

NasdaqGS:PYXS Stok Raporu

Piyasa değeri: US$122.9m

Pyxis Oncology Yönetim

Yönetim kriter kontrolleri 3/4

Pyxis Oncology CEO'su Tom Civik, Feb2026 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.35% doğrudan sahiptir ve bu hisselerin değeri $ 433.88K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.2 yıl ve 4.7 yıldır.

Anahtar bilgiler

Tom Civik

İcra Kurulu Başkanı

US$75.9k

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresiless than a year
CEO sahipliği0.4%
Yönetim ortalama görev süresi1.2yrs
Yönetim Kurulu ortalama görev süresi4.7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Analiz Makalesi • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analiz Makalesi • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Analiz Makalesi • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO

Tom Civik (56 yo)

less than a year
Görev süresi
US$75,904
Tazminat

Mr. Thomas Civik, also known as Tom, is Independent Chairman of the Board at ImCheck Therapeutics SAS since March 2023. He is Interim CEO & Director of Pyxis Oncology, Inc. from February 3, 2026. He was In...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Civik
Interim CEO & Directorless than a yearUS$75.90k0.35%
$ 433.9k
Jitendra Wadhane
Chief Accounting Officer4.8yrsUS$766.75kVeri yok
Balu Balasubramanian
Interim Chief Technology Officer4.3yrsVeri yokVeri yok
Alex Kane
Senior Vice President of Investor Relations & Capital Marketsless than a yearVeri yokVeri yok
Donna Regalado
Head of Human Resources1.3yrsVeri yokVeri yok
Charles Gombar
Senior Vice President of Portfolio & Program Management4.3yrsVeri yokVeri yok
Michael Bui
Senior Vice President of Global Regulatory Affairs1.2yrsVeri yokVeri yok
Supriya Roth
Head of Commercial Development1.2yrsVeri yokVeri yok
Shui He
Head of Biometrics1.2yrsVeri yokVeri yok
Hongwei Wang
Head of ADC Development & Clinical Strategy1.2yrsVeri yokVeri yok
Marsha Crochiere
Head of Translational Medicine & Research1.2yrsVeri yokVeri yok
Chris Cohen
Head of Drug Safety & Pharmacovigilance1.3yrsVeri yokVeri yok
1.2yrs
Ortalama Görev Süresi

Deneyimli Yönetim: PYXS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Civik
Interim CEO & Director4.7yrsUS$75.90k0.35%
$ 433.9k
John Flavin
Independent Chairman7yrsUS$155.90k0.66%
$ 807.6k
Anthony Tolcher
Member of Clinical & Translational Medicine Advisory Board4.9yrsVeri yokVeri yok
Freda Lewis-Hall
Independent Director4.7yrsUS$73.40k0.38%
$ 472.0k
Darren Cline
Independent Director4.7yrsUS$83.40k0.40%
$ 491.6k
Santhosh Palani
Independent Director2.2yrsUS$127.78k0%
$ 0
Jason J. Luke
Member of Clinical & Translational Medicine Advisory Boardno dataVeri yokVeri yok
Christopher O'Donnell
Member of Technical Advisory Board4.1yrsVeri yokVeri yok
Morris Rosenberg
Chairperson of Technical Advisory Boardno dataVeri yokVeri yok
Robert Baffi
Member of Technical Advisory Boardno dataVeri yokVeri yok
Virgil Lawlis
Member of Technical Advisory Boardno dataVeri yokVeri yok
Michael Sun
Member of Technical Advisory Boardno dataVeri yokVeri yok
4.7yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: PYXS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 16:32
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pyxis Oncology, Inc. 13 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.